Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 277 people enrolled
- Started
- 3 Apr 2024
- Ended
- 27 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MRSA Nasal Swab PCR
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult (age greater than or equal to 18) patients admitted/transferred to the Vanderbilt University Medical Center (VUMC) Medical Intensive Care Unit (MICU) from the VUMC Emergency Department or from a hospital floor within 48 hours of admission
- Suspicion for pneumonia on admission (defined as an indication for antibiotics of "respiratory infection" and/or an order for a respiratory culture i.e., sputum culture, tracheal aspirate culture, or bronchoalveolar lavage (BAL) culture)
- No topical nasal decolonization during hospitalization prior to collection of MRSA nasal swab PCR
- Must match both of the following in either order:; The patient has been admitted to and physically located in the MICU; The patient has received a continuing vancomycin order, or a pharmacokinetics consult for a continuing vancomycin order, no later than 24 hours following their physical admission to the MICU
Who cannot take part
- Hospital stay of longer than 48 hours prior to MICU admission
- Known to be a prisoner
Where in United States
- Vanderbilt University Medical CenterNashville, United States
About the trial
What the trial wants to find out
This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.
The 2 groups in the trial
- No MRSA Nasal SwabNo study treatment, for comparison
Subjects will not have a nasal swab collected.
- MRSA Nasal SwabExisting treatment, for comparison
Subjects will have a nasal swab collected and sent to the clinical laboratory for the MRSA nasal swab PCR test to be run. For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
Treatment: MRSA Nasal Swab PCR
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)
- Publications
- Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026
- Swab Testing to Optimize Pneumonia treatment with empiric Vancomycin (STOP-Vanc): study protocol for a randomized controlled trial.Trials, 2024
- Swab Testing to Optimize Pneumonia treatment with empiric Vancomycin (STOP-Vanc): study protocol for a randomized controlled trial.Research square, 2024
- Record updated
- 27 February 2026